nad+ nasal spray: Frequently asked questions

Administer the dose and wait 20–30 minutes before evaluating subjective response. NAD+ supports mitochondrial ATP production, not acute neurotransmitter release. The effect is metabolic substrate availability, not stimulant activation. Some users report mental clarity or reduced fatigue within 30–45 minutes, but these are downstream effects of improved cellular respiration, not direct CNS stimulation. If you feel nothing after consistent use over 7–10 days, assess baseline NAD+ status. Individuals with already-sufficient NAD+ pools may experience minimal subjective benefit because their mitochondria aren't substrate-limited.

Do not use it. Cloudiness indicates bacterial contamination or protein aggregation. Both render the preparation unsafe and ineffective. Bacterial growth in bacteriostatic water signals either a contaminated mixing process or storage temperature exceeding the preservative's effective range (above 10°C for extended periods). Protein aggregation occurs when NAD+ denatures due to pH shift, temperature excursion, or oxidative stress. Neither condition is reversible. Discard the vial, sterilise your workspace, and prepare a fresh batch using a new vial of lyophilised powder and fresh bacteriostatic water.

Use an insulin cooler with gel packs rated for 2–8°C maintenance. Standard options like the FRIO wallet use evaporative cooling and maintain temperature for 36–48 hours without electricity. For longer trips, portable medical refrigerators with USB or car adapter power (brands like Dometic or ARB) provide continuous monitoring. Do not attempt to maintain NAD+ nasal spray in a hotel mini-fridge unless you can verify its temperature stability with a standalone thermometer. Most cycle between 0–12°C during defrost, which will degrade your preparation.

NAD+ in solution is stable at room temperature (20–25°C) for 24–48 hours without significant degradation, but prolonged heat exposure (above 30°C) accelerates hydrolysis of the glycosidic bond linking nicotinamide to ribose. If the package was in transit for more than three days in warm conditions, request a replacement. There's no home test for NAD+ potency, and degraded product delivers nicotinamide instead of the intact coenzyme. Store all intranasal NAD+ at 2–8°C immediately upon receipt and use within 30 days of opening. Solutions that develop discolouration (yellowing or browning) indicate oxidative degradation and should be discarded.

Discard it. NAD+ in aqueous solution degrades rapidly at room temperature. After 12 hours at 20–25°C, expect potency loss exceeding 40%. The solution may appear clear and unchanged, but oxidative degradation is invisible. NAD+ is a redox-active coenzyme, meaning it reacts with dissolved oxygen in the solution even without visible contamination. Temperature accelerates this reaction exponentially. Every 10°C increase roughly doubles the degradation rate. By the time you notice cloudiness or discoloration, the compound is already completely inactive.

If you're responding well to NMN and have confirmed efficacy through biomarkers (improved energy, reduced fatigue, or measurable changes in metabolic markers), the decision to switch depends on absorption efficiency. Intranasal NAD+ delivers the coenzyme form directly, bypassing the NMN-to-NAD+ conversion step that salvage pathways require. For individuals with impaired NAMPT activity (common in aging populations or metabolic syndrome), NAD+ nasal spray may provide superior benefit because it doesn't rely on enzymatic conversion. The trade-off is cost. Research-grade intranasal NAD+ typically costs 2–3× more per milligram than bulk NMN powder.